$0.75
7.07% yesterday
Nasdaq, May 20, 09:48 pm CET
ISIN
US7530181004
Symbol
RANI
Sector
Industry

Rani Therapeutics Holdings Inc - Ordinary Shares Class A Stock price

$0.75
-0.34 31.28% 1M
-1.30 63.46% 6M
-0.62 45.32% YTD
-4.50 85.73% 1Y
-10.65 93.43% 3Y
-10.25 93.19% 5Y
-10.25 93.19% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.05 7.01%
ISIN
US7530181004
Symbol
RANI
Sector
Industry

Key metrics

Market capitalization $25.15m
Enterprise Value $32.18m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 26.82
P/S ratio (TTM) P/S ratio 20.96
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $1.20m
EBIT (operating result TTM) EBIT $-47.58m
Free Cash Flow (TTM) Free Cash Flow $-34.54m
Cash position $16.35m
EPS (TTM) EPS $-0.98
P/E forward negative
P/S forward 65.16
EV/Sales forward 83.37
Short interest 9.87%
Show more

Is Rani Therapeutics Holdings Inc - Ordinary Shares Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Rani Therapeutics Holdings Inc - Ordinary Shares Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Rani Therapeutics Holdings Inc - Ordinary Shares Class A forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Rani Therapeutics Holdings Inc - Ordinary Shares Class A forecast:

Buy
100%

Financial data from Rani Therapeutics Holdings Inc - Ordinary Shares Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1.20 1.20
-
100%
- Direct Costs 1.03 1.03
26% 26%
86%
0.17 0.17
112% 112%
14%
- Selling and Administrative Expenses 21 21
10% 10%
1,754%
- Research and Development Expense 26 26
32% 32%
2,139%
-47 -47
25% 25%
-3,879%
- Depreciation and Amortization 1.03 1.03
26% 26%
86%
EBIT (Operating Income) EBIT -48 -48
25% 25%
-3,965%
Net Profit -30 -30
10% 10%
-2,483%

In millions USD.

Don't miss a Thing! We will send you all news about Rani Therapeutics Holdings Inc - Ordinary Shares Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rani Therapeutics Holdings Inc - Ordinary Shares Class A Stock News

Neutral
GlobeNewsWire
one day ago
- Research agreement is evaluating feasibility of applying Rani's oral delivery technology to Chugai's antibodies against undisclosed targets - SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company...
Neutral
GlobeNewsWire
7 days ago
- Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 -
Neutral
Seeking Alpha
about 2 months ago
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Kiki Patel - IR, Gilmartin Group Talat Imran - CEO Svai Sanford - CFO Conference Call Participants Annabel Samimy - Stifel Eka Gigauri - Oppenheimer Julian Harrison - BTIG Mitchell Kapoor - H.C. Wainwright Chad Yahn - Maxim Group Xinwei An - Canaccord Genuity John Vand...
More Rani Therapeutics Holdings Inc - Ordinary Shares Class A News

Company Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage bio-therapeutics company providing technologies to enable the development of orally administered biologics. It offers RaniPill capsule, an orally ingestible pill for the administration of a broad range of biologics. The company was founded by Mir Imran on April 6, 2021 and is headquartered in San Jose, CA.

Head office United States
CEO Talat Imran
Employees 105
Founded 2012
Website www.ranitherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today